Drug Trial Radar · NCT02099058
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
237
Actual
Start
Jan 15, 2014
Primary completion
Aug 2026
Study completion Aug 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 28, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABBV-399 as monotherapy and in combination with osimertinib, erlotinib, and nivolumab in participants with advanced solid tumors likely to express c-Met. Enrollment is closed for the monotherapy arms, Arm A, and Arm D.
Conditions
- Advanced Solid Tumors Cancer
Interventions
OsimertinibDrug
It is administered orally everyday.
NivolumabDrug
It is an intravenous infusion administered every 14 days.
Telisotuzumab vedotinDrug
It is administered by infusion in 21-day dosing cycles.
Telisotuzumab vedotinDrug
It is administered by infusion in 28-day dosing cycles.
ErlotinibDrug
It is administered orally everyday.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse EventsTime frame: Up to 24 Months
- Recommended Phase 2 Dose (RPTD) of ABBV-399 when Administered as Monotherapy and in Combination with Osimertinib, Erlotinib or NivolumabTime frame: Up to 24 Months
- Area under the curve (AUC) from time zero to the last measurable concentration AUC (0-t)Time frame: Up to 24 months
- Maximum observed plasma concentration (Cmax)Time frame: Up to 24 months
- Time to Cmax (Tmax)Time frame: Up to 24 months
- Terminal elimination half lifeTime frame: Up to 24 months
Locations
36 sites in 9 countries. Site status is shown where the registry gives one.
Scottsdale Healthcare /ID# 123761
Scottsdale, Arizona
City of Hope /ID# 153759
Duarte, California
University of California, Los Angeles /ID# 148295
Los Angeles, California
UC Irvine /ID# 165107
Orange, California
University of California, Davis Comprehensive Cancer Center /ID# 129805
Sacramento, California
Univ of Colorado Cancer Center /ID# 123759
Aurora, Colorado
The University of Chicago Medical Center /ID# 136995
Chicago, Illinois
Ingalls Memorial Hosp /ID# 165876
Harvey, Illinois
Massachusetts General Hospital /ID# 129804
Boston, Massachusetts
Dana-Farber Cancer Institute /ID# 168782
Boston, Massachusetts
Duplicate_Henry Ford Health System /ID# 149857
Detroit, Michigan
Herbert Herman Cancer Center /ID# 149858
Lansing, Michigan
Washington University-School of Medicine /ID# 143798
St Louis, Missouri
Summit Medical Group-Florham Park /ID# 217651
Florham Park, New Jersey
Northwell Health - Monter Cancer Center /ID# 218170
Lake Success, New York
Montefiore Medical Park at Eastchester /ID# 218445
The Bronx, New York
Duke Cancer Center /ID# 123763
Durham, North Carolina
Tennessee Oncology, PLLC /ID# 129802
Nashville, Tennessee
Mary Crowley Cancer Research /ID# 123760
Dallas, Texas
University of Texas MD Anderson Cancer Center /ID# 154648
Houston, Texas
Virginia Cancer Specialists - Fairfax /ID# 165708
Fairfax, Virginia
Universitair Ziekenhuis Antwerpen /ID# 170118
Edegem, Antwerpen, Belgium
Duplicate_Tampere University Hospital /ID# 165065
Tampere, Pirkanmaa, Finland
AP-HM - Hopital de la Timone /ID# 151570
Marseille, Bouches-du-Rhone, France
Institut Gustave Roussy /ID# 132747
Villejuif, Val-de-Marne, France
Duplicate_Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRCCS /ID# 164077
Meldola, Emilia-Romagna, Italy
National Cancer Center Hospital East /ID# 217570
Kashiwa-shi, Chiba, Japan
National Cancer Center Hospital /ID# 217571
Chuo-ku, Tokyo, Japan
Radboud Universitair Medisch Centrum /ID# 246908
Nijmegen, Gelderland, Netherlands
Yonsei University Health System Severance Hospital /ID# 217333
Seoul, South Korea
Duplicate_The Catholic University of Korea, ST. Vincent's Hospital /ID# 233378
Suwon, Gyeonggido, South Korea
Asan Medical Center /ID# 217334
Seoul, Seoul Teugbyeolsi, South Korea
China Medical University Hospital /ID# 217494
Taichung, Taichung, Taiwan
National Cheng Kung University Hospital /ID# 167175
Tainan, Tainan, Taiwan
Taipei Veterans General Hosp /ID# 217392
Taipei, Taipei, Taiwan
National Taiwan University Hospital /ID# 167173
Taipei City, Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.